A DNA-based multi-gene panel test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) to detect variants in at least EGFR, BRAF, KRAS and MET exon 14; and (b) to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (c) not associated with a service to which item 73437, 73337, 73436 or 73351 applies
A DNA-based multi-gene panel test of tumour tissue from a patient with a new diagnosis of non-small cell lung cancer requested by, or on behalf of, a specialist or consultant physician, if the test is: (a) to detect variants in at least EGFR, BRAF, KRAS and MET exon 14; and (b) to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme; and (c) not associated with a service to which item 73437, 73337, 73436 or 73351 applies
| Release | Change | Old | New |
|---|---|---|---|
| November 2025 | UPDATED | $682.35 | $682.35 |
Data sourced from Australian Government publications · Not an official government service